FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

Keyphrases

• Placebo 100%
• Twice Daily 100%
• Moderate-to-severe Psoriasis 100%
• Dose-ranging Study 100%
• Long-term Extension 100%
• Investigator's Global Assessment 66%
• Adverse Events 33%
• Serious Adverse Events 33%
• Interleukin-23 (IL-23) 33%
• Treatment Group 33%
• Receptor Signaling 33%
• Response Rate 33%
• High Response Rate 33%
• Psoriasis Area 33%
• Area Index 33%
• Severity Index 33%
• PASI100 33%
• Skin Clearance 33%
• PASI 75 33%
• Clear or Almost Clear Skin 33%
• PASI90 33%
• Oral Peptides 33%
• Outcome Response 33%
• Patient numbers 33%
• Safety Signal 33%
• Psoriasis Severity 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Psoriasis Vulgaris 100%
• Placebo 100%
• Adverse Event 66%
• Psoriasis 33%
• Interleukin 23 Receptor 33%
• Treatment Group 33%
• Peptide 33%